An index compiling 30 stocks that track the biomedical industry in the Guangdong-Hong Kong-Macao Greater Bay Area was unveiled at the 2019 Shenzhen International Biotech Conference yesterday.
Representatives from the top biotech enterprises in Shenzhen receive award certificates at the 2019 Shenzhen International Biotech Conference yesterday. Zhang Yu
The index aims to monitor the trends of the health-care sector in the Greater Bay Area, guide market resources to high-quality enterprises, provide reference for decision-making and expedite the upgrading of the biomedical industry in the Greater Bay Area.
The index was jointly launched by China Center for Information Industry Development and Shenzhen Securities Information Co. Ltd.
The conference also released a list of the top 20 biotech enterprises in Shenzhen, making a quantitative evaluation of these companies from the perspectives of management team, technology, product, market and financing.
This year’s conference features two keynote speeches, two high-end dialogues and five professional forums covering topics in the biotech industry, such as innovative drugs, high-end biomedical engineering and big data in health care.
It has invited 70 renowned academicians and entrepreneurs from home and abroad to carry out academic exchanges, policy analysis and industrial cooperation.
The biomedical industry has been regarded as a key industry by the Shenzhen government in recent years. The output value of the biomedical industry in Shenzhen has exceeded 280 billion yuan (US$39.34 billion), with a year-on-year growth rate of 20 percent, according to official data.
Shenzhen has hosted the conference, previously known as Shenzhen International Biotech Summit, for five consecutive years. The two-day conference kicked off at the Shenzhen Convention and Exhibition Center yesterday.